- FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database.
- The company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026.
- The company’s current estimates project that the trial cost will be around $60 million.
- https://stocktwits.com/news-articles/markets/equity/why-did-rvph-stock-crash-50-today/cLepAbRREH3
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.